Supplement Dupilumab in prurigo nodularis: 52-week effectiveness and safety from the prospective multicenter BioDay registry

Supplemental Material: Supplement 1. Extended methods Table S1. Baseline characteristics Table S2. Effectiveness outcomes during 52 weeks of treatment with dupilumab for prurigo nodularis Figure S1. Effectiveness outcomes IGA PN-S, PP-NRS, DLQI, and NRS sleep deprivation over time Figure S2. Effectiveness of dupilumab in patients with and without comorbid atopic dermatitis Table S3 Effectiveness outcomes differentiated by history of atopic dermatitis, history of any atopic comorbidity, and sex Table S4. Adverse events reported during follow-up Table S5. Serious Adverse Events reported during follow-up